Genascence Announces Data From Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, Presented at American Society of Gene & Cell Therapy 25th Annual Meeting
- Tuesday, May 17, 2022, 7:00
- Finance
- Add a comment
Additional safety data, including 12-month follow-up on all subjects, demonstrated GNSC-001 is safe and well tolerated Injection of GNSC-001 was associated with increased synovial concentrations of IL-1Ra and improved pain and function scores Osteoarthritis affects more than 30 million…
About the Author
adminasapcorp has written 41616 stories on this site.